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The pre-steady states of Pseudomonas species lipase inhibitions by p-nitrophenyl-N-substituted
carbamates (1–6) are composed of two steps: (1) formation of the non-covalent enzyme–
inhibitor complex (E:I) from the inhibitor and the enzyme and (2) formation of the tetrahedral
enzyme–inhibitor adduct (E–I) from the E:I complex. From a stopped-ﬂow apparatus, the
dissociation constant for the E:I complex, KS, and the rate constant for formation of the
tetrahedral E–I adduct from the E:I complex, k2 are obtained from the non-linear least-
squares of curve ﬁttings of ﬁrst-order rate constant (kobs) versus inhibition concentration ([I])
plot against kobs=k2+k2[I]/(KS+[I]). Values of pKS, and log k2 are linearly correlated with
the r* values with the q* values of )2.0 and 0.36, respectively. Therefore, the E:I complexes are
more positive charges than the inhibitors due to the q* value of )2.0. The tetrahedral E–I
adducts on the other hand are more negative charges than the E:I complexes due to the q*
value of 0.36. Formation of the E:I complex from the inhibitor and the enzyme are further
divided into two steps: (1) the pre-equilibrium protonation of the inhibitor and (2) formation
of the E:I complex from the protonated inhibitor and the enzyme.
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1. INTRODUCTION
Lipases (EC 3.1.1.3) are lipolytic enzymes and cata-
lyze hydrolysis of the ester bonds of triacylglycerols
(Svendsen, 1994). Moreover, lipases may also
catalyze the hydrolysis of a wide range of ester
substrates. Because of the broad substrate speciﬁcity
and high substrate enantioselectivity, lipases have
found widespread applications in enantioselective
synthesis of organic compounds and resolution of
racemates (Boland et al., 1991; Theil, 1995).
All lipases contain the a/b hydrolase fold, a
structural motif common to a wide variety of
hydrolases (Ollis et al., 1992). From X-ray crystal
structures of various lipases (Grochulski et al.,
1994; Kim et al., 1997; Lang et al., 1998; Schrag
et al., 1997; van Tilbeurgh et al., 1993), their active
Abbreviations: ACS, the ﬁrst acyl chain binding site; CEase, cho-
lesterol esterase; CRL, Candida rugosa lipase; CS, the catalytic side;
d, the intensity factor of a reaction to the substituent steric eﬀects;
E, enzyme; Es, Taft steric substituent constant; E–I, tetrahedral
enzyme-inhibitor adduct; E:I, non-covalent enzyme-inhibitor
complex in the pre-steady state; E–I’, carbamyl enzyme; I, inhibi-
tor; k2, rate constant for formation of E–I from E:I in the pre-
steady state; k)2, rate constant for re-dissociation of E–I to E:I in
the pre-steady state; kc, carbamylation constant or rate constant for
the formation of E–I’ from E–I; kd, decarbamylation or rate con-
stant for hydrolysis of E–I’ to product; Ki, inhibition constant or
dissociation constant of the steady state; ki, bimolecular inhibition
constant (=kc/ki); Ks, dissociation constant of E:I in the pre-steady
state (=k1/k)1); OAH, oxyanion hole; PCL, Pseudomonas cepacia
lipase; PSL, Pseudomonas species lipase; PNPB, p-nitrophenylbu-
tyrate; QSAR, quantitative structure-activity relationship; R, cor-
relation coeﬃcient; q*, intensity factor of a reaction to the
substituent electronic eﬀects; SACS, the second acyl chain binding
site; r, Hammett substituent constant; r*, Taft inductive sub-
stituent constant; TACS, the third acyl chain binding site.
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sites contain a catalytic triad, Ser-His-Asp/Glu, sim-
ilar to those serine proteases, acetylcholinesterase
(AChE) (Bar-On et al., 2002; Bartolucci et al., 1999;
Harel et al., 1996; Sussman et al., 1991), and cho-
lesterol esterase (CEase) (Chen et al., 1998; Wang
et al., 1997). The conservation of this catalytic triad
suggests that as well as sharing a common mecha-
nism for substrate hydrolysis, that is, formation of
a discrete acyl enzyme intermediate from the nucle-
ophilic attack of the active site serine hydroxyl
group to the substrate carbonyl group, AChE, ser-
ine proteases, CEase, and lipases may well be
expected to be inhibited by the same classes of
mechanism-based inhibitor. To date, this has been
demonstrated for carbamates (Bar-On et al., 2002;
Bartolucci et al., 1999; Cavalier et al., 2000; Feaster
et al., 1996; Fourneron et al., 1991; Hosie et al.,
1987; Lin and Chouhwang, 2001; Lin and Lai,
1995, 1996; Lin et al., 1999a, b, c, 2000a, b, 2003a,
b, 2004a, b, c; Simons et al., 1997), chiral phospho-
nates (Lang et al., 1998), hexadecylsulfonyl ﬂuoride
(Grochulski et al., 1994), ﬂuoroketones (Allen and
Abeles, 1989; Brady et al., 1989; Harel et al., 1996;
Imperiali and Abeles, 1986; Kokotos et al., 2003;
Sohl et al., 1988), and bornic acid (Koehler and
Hess, 1974; Nakatani et al., 1975a; Seufer-Wasser-
thal et al., 1994; Simpelkamp and Jones, 1992;
Steiner et al., 1994).
Although diﬀerent activation mechanisms are
proposed, the active sites of Pseudomonas cepacia
lipase (PCL) (Kim et al., 1997; Lang et al., 1998;
Schrag et al., 1997), Candida rugosa lipase (CRL)
(Grochulski et al., 1994), AChE (Bar-On et al.,
2002; Bartolucci et al., 1999; Harel et al., 1996;
Sussman et al., 1991), and CEase (Chen et al., 1998;
Wang et al., 1997) are similar to each other. The
active site of PCL consists of ﬁve major binding
sites (Lang et al., 1998; Kim et al., 1997; Schrag
et al., 1997) (Fig. 1): (a) the acyl binding site (ACS), a
hydrophobic groove of 0.8  1.0 nm in width,
comprised of Pro113, Leu17, Phe119, Leu164,
Leu167, Va1266, and Va1267, which binds to the
ﬁrst (sn)1 or sn)3) acyl chain of triacylglycerol via
van der Waals’ interactions, (b) the oxyanion hole
(OAH), the hydrogen bonding peptide NH function
of Leu17 and Gln88, which stabilizes the incipient
carbonyl C–O) of the ester function during turn
over, (c) the catalytic site (CS), Ser87–His286–
Asp264, comprised of the active site Ser which
wound attack the carbonyl carbon of the substrate,
(d) the second acyl chain binding site (SACS),
Leu287, Leu293, and Thr18, located in a crevice
above ES, which may bind to the second (sn–2)
acyl chain of triacylglycerol via van der Waals’
interactions, and (e) the third acyl chain binding
site (TACS), Ala247 and Thr251, located at the
opposite direction of ACS, which may bind to
the third (sn–3 or sn–1) acyl chain of triacylglyc-
erol via a small number of van der Waals’
interactions.
The lipase-catalyzed hydrolysis of lipid sub-
strates via a serine protease mechanism has been
proposed (Fourneron et al., 1991; Lin and Chouhw-
ang, 2001; Lin et al., 1999a, 2003a; Simons et al.,
1997). In the presence of substrate, the pseudo-sub-
strate of Pseudomonas species lipase (PSL) inhibi-
tion mechanism by aryl carbamates has been
proposed (Scheme 1).
Because the PSL inhibition follows ﬁrst-order
kinetics over the observed time period for the stea-
dy-state kinetics, the hydrolysis rate of E–I’
(decarbamylation constant, kd) must be signiﬁcantly
slower than the formation rate of EI’ (carbamyla-
tion constant, Kc) (Simons et al., 1997). The inhibi-
tion constant (Ki) and kc for the steady-state of the
PSL inhibitions by carbamates are obtained from
the non-linear least-squares of curve ﬁttings of the
ﬁrst-order rate constant (kapp) versus concentration
of the inhibitor ([I]) plot against equation 1 (Feaster
et al., 1996; Hosie et al., 1987):
kapp ¼ kc½I=Kið1þ ½S=KmÞ þ ½I ð1Þ
In Eq. (1), kapp can be obtained by Hosie’s method
(Feaster et al., 1996; Hosie et al., 1987). Bimolecu-
lar inhibition constant (ki=kc/Ki) is related to over-
all inhibitory potency.
The pre-steady state of an enzyme inhibition
mechanism has been proposed (Scheme 2), where
k1,k)1,k2 and k)2 are the rate constants for forma-
tion of the enzyme–inhibitor complex (E:I), for
re-dissociation of E:I, for formation of E–I, and
re-dissociation of E–I, respectively (Fersht, 1984;
Hart, 1974; Ikeda et al., 1982; Nakatani et al.,
1975a, b, 1977, 1978). Moreover, values of
KS(=k)1/k1), k2 and k)2 are obtained from the non-
linear least squares of curve ﬁttings of the ﬁrst-order
rate constant (kobs) versus [I] plot against Eq. (2).
kobs ¼ k2 þ k2½I=ðKS þ ½IÞ ð2Þ
In Eq. (2), kobs and KS are the ﬁrst-order rate
constant and dissociation constant of the E:I com-
plex in the pre-steady state, respectively. Therefore,
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Fig. 1. The proposed mechanism for the PSL inhibitions by carbamates 1–6. The ﬁrst step is the pre-equilibrium protonation of the
inhibitor. The conformation for both inhibitor and protonated inhibitor is pseudo-trans one. The second step is formation of the non-
covalent enzyme-inhibitor complex (E:I). The conformation for the inhibitor in this complex is pseudo-cis (Lin et al., 2003a). The third
step is formation of the tetrahedral enzyme–inhibitor adduct (E–I) from the E:I complex. This step involves a nucleophilic attack of the
active site Ser87 to the carbamate carbonyl group of the inhibitor. The fourth step is formation of the carbamyl enzyme from the tetrahe-
dral E–I adduct.
Scheme 1. Kinetic scheme for the steady state of pseudo-substrate inhibition of PSL in the presence of substratea. aE, enzyme; S, sub-
strate; I, carbamate inhibitor; E–I, tetrahedral enzyme–inhibitor adduct; E–I’, carbamyl enzyme; kc carbamylation constant or formation
rate constant of E–I’; kd, decarbamylation or hydrolysis rate constant of E–I’; Ki, inhibition or dissociation constant.
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the inhibition constant, Ki equals to KS k)2/k2
(Eq. (3)).
1=Ki ¼ ð1=KSÞðk2=k2Þ ð3Þ
Quantitative structure-activity relationships (QSARs)
for the steady states of CEase (Feaster et al., 1996;
Lin and Lai, 1995, 1996; Lin et al., 1999a, 2000b,
2004b), AChE (Lin, 2004; Lin et al., 2000b, 2004a),
and PSL (Lin and Chouhwang, 2001; Lin et al.,
1999a, 2003a; Simons et al., 1997) inhibitions by
carbamates have been reported. QSARs for the pre-
steady states of CEase (Lin et al., 2000a) and AChE
(Lin et al., 2004c) inhibitions by carbamates have
been also reported. In this paper, we further report
QSARs for the pre-steady state of the PSL inhibi-
tions by carbamates 1–6. Furthermore, the mecha-
nism for pre-steady state of PSL inhibition by the
carbamate inhibitor is proposed.
2. MATERIAL AND METHODS
2.1. Materials
PSL and p-nitrophenyl butyrate (PNPB) were
obtained from Sigma; other chemicals were obtained
from Aldrich; silica gel used in liquid chromatogra-
phy (Licorpre Silica 60, 200–400 mesh) and thin-layer
chromatography plates (60 F254) were obtained
from Merck; other chemicals were of the highest
quality available commercially. p-Nitrophenyl-N-
substituted carbamates (1–6) were prepared from con-
densation of p-nitrophenol and the corresponding iso-
cyanate (Lin and Chouhwang, 2001; Lin et al., 2000b).
2.2. Instrumental Methods
1H and 13C NMR spectra were recorded at 300
and 75.4 MHz, respectively, on a Varian-XL 300
spectrometer. The 1H and 13C chemical shifts were
referred to internal tetramethylsilane. Pre-steady
state kinetic data were obtained from an UV-visible
spectrometer (HP 8452A, Beckman DU-650, or Ag-
lient 8453) equipped with a stopped ﬂow apparatus
(Hi-Tech SFA-20 or Applied Photo Physics RX-
2000). The pKa values were obtained from the pH-
stat-titration (Radiometer PHM 290).
2.3. Data Reduction
Origin (version 6.0) was used for linear and
nonlinear least squares of curve ﬁttings.
2.4. Steady State of Enzyme Kinetics
The pseudo-substrate inhibitions of PSL by
carbamates 1–6 were reported before (Lin and Cho-
uhwang, 2001). The temperature was maintained at
25.0C by a refrigerated circulating water bath. All
reactions were performed in sodium phosphate buf-
fer (1 ml, 0.1 M, pH 7.0) containing NaCl (0.1 M),
acetonitrile (2% by volume), triton X-100 (0.5% by
weight), substrate (0.2 mM of PNPB), and varying
concentration (from 10)8 to 10)3 M) of inhibitors.
Requisite volumes of stock solution of substrate
and inhibitors in acetonitrile were injected into reac-
tion buﬀer via a pipet. Porcine pancreatic PSL was
dissolved in sodium phosphate buﬀer (0.1 M,
pH 7.0). Reactions were initiated by injecting en-
zyme {10 lg 0.5 unit (lmole/min) of PSL} and
monitored at 410 nm on the UV-visible spectrome-
ter. First-order rate constants (kapp) were deter-
mined by non-linear least squares of curve ﬁttings
on the absorbances versus time plot (Feaster et al.,
1996; Hosie et al., 1987). Values of Ki were ob-
tained from non-linear least squares of curve ﬁttings
on kapp versus [I] plot against Eq. (1) (Hosie et al.,
1987). Duplicate or triplicate sets of data were col-
lected for each inhibitor concentration.
2.5. Pre-steady State of Enzyme Kinetics
The PSL-catalyzed hydrolysis of PNPB was
followed continuously at 410 nm in presence and
absence of an inhibitor on an UV-visible spectrome-
ter equipped with a stopped-ﬂow apparatus. One
syringe of the apparatus contained the enzyme
(1 lg) in the buﬀer solution (1 ml, 0.1 M NaCl,
Scheme 2. Kinetic scheme for the pre-steady state of pseudo-sub-
strate inhibition of PSLa. aE:I, non-covalent enzyme-inhibitor
complex; k2, rate constant for formation of the E–I adduct from
the E:I complex; k)2, rate constant for re-dissociation of the E–I
adduct to the E:I complex; k1, rate constant for formation of the
E:I complex; k)1, rate constant for re-dissociation of the E:I
complex.
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0.1 M phosphate buﬀer, pH 7.0) and the other syr-
inge contained PNPB (200 lM) in the buﬀer solu-
tion (1 ml) and varying concentration of carbamates
1–6 (from 10)8 to 10)10). The reaction temperature
was kept at 25.0C. All reastion and cycle times
were 60 s and 0.1 s, respectively.
First-order rate constants (kobs) for inhibition
of CEase by carbamates 1–6 were determined. The
KS, and k2 values were obtained by non-linear least
squares of curve ﬁttings of kobs versus [I] plot
against Eq. (2), The k)2 values were calculated from
Eq. (3). Duplicate or triplicate sets of data were col-
lected for each inhibitor concentration.
3. RESULTS
3.1. Steady State of Inhibition
Carbamates 1–6 are characterized as the pseu-
do-substrate inhibitors of PSL and the Ki values
were obtained from non-linear least squares of
curve ﬁtting of Eq. (1) as described before (Lin and
Chouhwang, 2001). Further, the linear correlation
between pKi values and r
* was observed (Eq. 4)
(Connors, 1990; Isaacs, 1995; Lowry and Richard-
son, 1987) and the slope (q*) for this correlation
was 1.7±0.2 (Lin and Chouhwang, 2001).
pKi ¼ qr þ h ð4Þ
3.2. Pre Steady State of Inhibition
The KS and k2 values (Table 1) were obtained
from the non-linear least squares of curve ﬁttings of
the kobs (or 1/T) values versus [I] plot against Eq.
(2) (Lin et al., 2000a, 2004c). The KS values for p-
nitrophenyl-N)n-alkylcarbamates (1–3) are much
lower than those for carbamates 3–6 (Table 1). Sim-
ilarly to Eq. (4), the linear correlation between pKS
and r* was also observed and the q* value for this
correlation was )2.0±0.1 (Table 2). The k2 values
were about the same; moreover, the k2 steps were
the rate determining steps for the pre-steady states
of formations of the tetrahedral E–I adducts
(Table 1). The log k2 values were linearly correlated
with r* and the q* value for this correlation was
0.36±0.03 (Table 2). The k)2 values were also
about the same but much less (<1/20) than the k2
values (Table 1). The log k)2 values were not corre-
lated with r* at all (Table 2). The log (k2/k)2) val-
ues were fairly correlated with r* and the q* value
for this correlation was 0.3±0.2 (Table 2).
4. DISCUSSION
4.1. Steady State of Inhibition
Carbamates 1–6 are characterized as the pseu-
do-substrate inhibitors of PSL (Lin and Chouhw-
ang, 2001). The q* value of )1.7±0.2 for the
pKi)r
* correlation (Table 2) indicates that the tet-
rahedral E–I adducts (Scheme 1) are more positive
charges than reactions (CEase and inhibitor). How-
ever, the tetrahedral E–I adducts (Fig. 1) are more
negative charges than carbamates 1–6. Therefore,
the Ki step composes at least two steps in the pre-
steady state.
4.2. Pre-steady State Inhibition
4.2.1. KS Step
The q* value of )2.0±0.1 for the pKS)r
* cor-
relation indicates that the non-covalent E:I com-
plexes (Scheme 2) are more positive charges than
carbamates 1–6, Carbamates 1–6 are protonated in
pre-equilibrium at pH 7 (Fig. 1) with the q* value
of )1.4±0.2 for the pKa)r
* correlation (Lin et al.,
2000b, 2003b). Therefore, formation of the E:I com-
plexes from PSL and carbamates 1–6 is composed
of two steps (Fig. 1): (1) the pre-equilibrium pro-
tonation and (2) formation of the E:I complexes
from PSL and protonated carbamates 1–6 with the
virtual dissociation constant of the E:I complex,
KS’. Thus, the q
* value for the pKS)r
* correlation
is calculated to be )0.6 ± 0.1 (Fig. 1). The q* value
of )0.6 suggests that the E:I complexes are more
positive charges than the protonated inhibitors
(Fig. 1). Electrostatic potential calculations show
that the region at Glu208 and Asp452, near the
mouth of tunnel has one of the most negative
potentials in CRL (Grochulski et al., 1994). There-
fore, the positive charges increase in the E:I com-
plex may be due to the ionic interaction between
the region of the negative charges and the proton-
ated inhibitor (Fig. 1).
The KS values for p-nitrophenyl-N-n-alkylcar-
bamates (1–3) are much lower than those for carba-
mates 3–6 (Table 1). In other words, carbamates 1–3
are easier to enter the ACS tunnel (Fig. 1) than car-
bamates 4–6. It is reasonable that the chlorine
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atom, phenyl group, or allyl group in carbamates
4–6 repulses the negative region of the enzyme and
this repulsion make the carbamate moieties of car-
bamates 4–6 diﬃcult to pass the ACS tunnel.
4.2.2. k2 Step
The q* value of 0.36±0.03 for the log k2)r
*
correlation (Table 2) indicates that the tetrahedral
E–I adducts are more negative charges than the E:I
complexes, Therefore, the k2 step involves a nucleo-
philic attack of the active site serine to the carba-
mate carbonyl group of the inhibitor (Fig. 1) and is
the rate determining steps for the pre-steady states
of formations of the tetrahedral E–I adducts. The
q* value of the log k2)r
* correlation for PSL inhi-
bitions by carbamates 1–6 is less than that for
CEase inhibitions by carbamates 1–6 (0.9) (Lin
et al., 2000a). The conformation of the carbamate
inhibitor changes from pseudo-trans to pseudo-cis
one during the PSL-catalyzed reaction (Lin et al.,
2003a) (Fig. 1) but the conformation of the carba-
mate inhibitor retains in pseudo-trans one during
the CEase-catalyzed reaction (Lin et al., 2004a). It
is possible that the pseudo-cis conformation of the
inhibitor is less reactive to the catalytic serine than
the pseudo-trans one.
4.2.3. k)2 Step
That the log k)2 values are not correlated with
r* (Table 2) may due to two reasons: (1) the k)2
values are calculated from too many mathematic
transformations and (2) the q* value for the log
k)2)r
* correlation is null (Table 2). Lack of the log
k)2)r
* correlation also lowers the log (k2/k)2)r
*
correlation.
Overall, both pre-steady state and steady state
of the PSL inhibition mechanisms by carbamates 1–
6 are proposed (Fig. 1).
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